Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP50: The landscape of somatic mutations in non-neoplastic IBD-affected colonECCO'20 Vienna
Year: 2020
Authors: Carl Anderson
Files: 1
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel DiseasesECCO'20 Vienna
Year: 2020
Authors: Federica Branchi
Files: 1
DOP52: The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s Disease or Ulcerative Colitis reflects the respective diseaseECCO'20 Vienna
Year: 2020
Authors: Anna Unterweger
Files: 1
DOP54: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesisECCO'20 Vienna
Year: 2020
Authors: Dezso Modos
Files: 1
DOP55: A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in Ulcerative Colitis: Results from EVOLVEECCO'20 Vienna
Year: 2020
Authors: Gerassimos Mantzaris
Files: 1
DOP56: Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe Ulcerative Colitis: Results from the UNIFI long-term extensionECCO'20 Vienna
Year: 2020
Authors: William Sandborn
Files: 1
DOP57: Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicenter, retrospective case-control studyECCO'20 Vienna
Year: 2020
Authors: Nathaniel Aviv Cohen
Files: 1
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort studyECCO'20 Vienna
Year: 2020
Authors: Jasmijn Sleutjes
Files: 1
DOP59: Maintenance of remission with tofacitinib in patients with Ulcerative Colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE OpenECCO'20 Vienna
Year: 2020
Authors: Walter Reinisch
Files: 1
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)ECCO'20 Vienna
Year: 2020
Authors: Silvio Danese
Files: 1
DOP61: Tofacitinib, an oral, small molecule Janus kinase inhibitor, in the treatment of Ulcerative Colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatmentECCO'20 Vienna
Year: 2020
Authors: Donna Judd
Files: 1
DOP62: Morbidity after primary ileocecal resection for Crohn’s Disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centreECCO'20 Vienna
Year: 2020
Authors: Matteo Rottoli
Files: 1
DOP63: Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with Inflammatory Bowel Disease: A randomized controlled trialECCO'20 Vienna
Year: 2020
Authors: Gionata Fiorino
Files: 1
DOP64: Discovery of highly selective small molecule oral inhibitors of integrin α4β7 for the treatment of Inflammatory Bowel DiseasesECCO'20 Vienna
Year: 2020
Authors: Jamie Wong
Files: 1
DOP67: CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signaling pathwayECCO'20 Vienna
Year: 2020
Authors: Jieun Shin
Files: 1
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centresECCO'20 Vienna
Year: 2020
Authors: Desmond Chee
Files: 1
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel DiseaseECCO'20 Vienna
Year: 2020
Authors: Peter Hasselblatt
Files: 1
DOP71: Efficacy, safety, and tolerability of ustekinumab in pediatric patients with moderately to severely active Crohn’s Disease: Results from, UniStar, a phase 1 studyECCO'20 Vienna
Year: 2020
Authors: Joel Rosh
Files: 1
DOP72: Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of Ulcerative Colitis: The open-label, multicentre, Phase 2a TUSCANY studyECCO'20 Vienna
Year: 2020
Authors: Silvio Danese
Files: 1
DOP73: Efficacy and safety of escalation to tofacitinib 10mg BID for patients with UC following loss of response on 5mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension studyECCO'20 Vienna
Year: 2020
Authors: Alessandro Armuzzi
Files: 1